VBIV

VBI Vaccines signs agreement with Canada to develop COVID-19 vaccine by 2022

Sept 21 (Reuters) - VBI Vaccines Inc VBIV.O said on Monday it had entered into an agreement with Canada to develop a potential vaccine for COVID-19 by 2022 through mid-stage trials conducted exclusively in the country.

Canada will contribute around 75% of the U.S.-based company's development costs and C$55.9 million ($42.2 million) for the project.

VBI Vaccines said last month that together with the National Research Council Canada it was investigating the vaccine candidate, VBI-2900, in preclinical trials.

As per the agreement, signed last week, the company's Ottawa-based unit is obligated to complete the vaccine development in or before the first quarter of 2022.

There are currently no approved vaccines for COVID-19, but around 38 vaccines are being tested in humans around the world.

($1 = C$1.32)

(Reporting By Mrinalika Roy in Bengaluru; Editing by Maju Samuel)

((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.